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Use of   Traditional Chinese Medication for post-stroke recovery
Shaista Anwar Sidddiqi,1 Ayeesha Kamran Kamal2
Stroke Fellow,1 Stroke Program,2 Section of Neurology, Department of Medicine, Aga Khan Hospital, Karachi.
More than 100 traditional Chinese medicines
(TCM) are being used in patients with stroke to enhance
post-stroke recovery in China and other parts of the world
for many years.  These medicines have been claimed to
have anti-oxidant, anti-inflammatory and anti-glutamate
affects, in addition to their ability to dilate blood vessels,
suppress platelet aggregation, protect against reperfusion
injury and to increase the tolerance of the ischemic tissue
to hypoxia.
Though, their safety profile has been projected to
be adequately reasonable, no convincing data has come up
yet to prove its efficacy in post-stroke recovery. Danqi
Piantang Jiaonang is one of these medicines which is
marketed internationally with the name of Neuroaid. It has
been tested in two randomized trials against another
Chinese traditional medicine, Buchang Naoxintong
Jiaonang (BNJ). 
What were the methods?
Both of these trials were conducted at 6 medical
centers in China. Patients with recent ischaemic stroke
diagnosed according to the Western medical standards
were enrolled.  Patients were enrolled both as in-patient
and out-patient after a signed informed consent. There
were 200 patients in the first trial and 405 patients in the
second trial. Patients were enrolled if they had a recent
ischaemic stroke (between 15 days to 6 months;
restoration stage according to TCM criteria) , an age range
between 18-70 years.
The pooled analysis of these trials was analyzed to
assess the safety and efficacy of the two study drugs. 
What were the results?
No difference was seen in gender, age, time from
stroke onset, or stroke severity score between the two
groups. Mean age was 58 years and majority of patients
were male. Over 30% patients in both the groups were
enrolled after 60 days of stroke. The analysis suggested
that as compared to BNJ, the patients in the Neuroaid
group were more likely to gain improvement in the
functional outcome score at 1 month. However no
significant benefit was observed in either group in terms of
neurological deficit score and individual scores. The only
side effects reported were nausea and vomiting.
What are the limitations of study?
The efficacy of Neuroaid was tested against another
similar medication without  many comparisons with a
placebo agent. The patient population was very heterogenous
in terms of time from stroke onset with a significant
proportion of patients recruiting after 120 days. Lack of data
about the etiologic classification of stroke; the co morbid
conditions like hypertension etc; the use of antiplatelet or
other therapeutic agents; concomitant rehabilitation therapy;
as well as lack of long-term follow up require that more data
from randomized controlled trials report the projected
positive effect of Neuroaid on the functional outcome of these
patients. It is also noteworthy that brain has a natural ability
of neuronal plasticity and recovery especially in the first few
months of stroke. Therefore, the efficacy of Neuroaid in post-
stroke recovery still remains to be proven as an adjunct for
post-stroke recovery in patients with ischaemic stroke.  A
larger trial is planned and results eagerly awaited due to its
favourable side effect profile. 
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